Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.
Sci Rep. 2022 Oct 1;12(1):16489. doi: 10.1038/s41598-022-20573-1.
One of the most widely used techniques in microbiota research is 16S-rRNA-sequencing. Several laboratory processes have been shown to impact sequencing results, especially in low biomass samples. Low biomass samples are prone to off-target amplification, where instead of bacterial DNA, host DNA is erroneously amplified. Knowledge on the laboratory processes influencing off-target amplification and detection is however scarce. We here expand on previous findings by demonstrating that off-target amplification is not limited to invasive biopsy samples, but is also an issue in low bacterial biomass respiratory (mucosal) samples, especially when below 0.3 pg/μL. We show that off-target amplification can partly be mitigated by using gel-based library purification methods. Importantly, we report a higher off-target amplicon detection rate when using MiSeq reagent kit v3 compared to v2 (mean 13.3% vs 0.1% off-target reads/sample, respectively), possibly as a result of differences in reagents or sequencing recipes. However, since after bioinformatic removal of off-target reads, MiSeq reagent kit v3 still results in a twofold higher number of reads when compared to v2, v3 is still preferred over v2. Together, these results add to the growing knowledge base on off-target amplification and detection, allowing researchers to anticipate this problem in 16S-rRNA-based microbiome studies involving low biomass samples.
在微生物组研究中,最广泛使用的技术之一是 16S-rRNA 测序。已经有多项实验室流程被证明会影响测序结果,尤其是在低生物量样本中。低生物量样本容易发生非靶向扩增,即错误地扩增宿主 DNA 而不是细菌 DNA。然而,关于影响非靶向扩增和检测的实验室流程的知识却很匮乏。我们通过展示非靶向扩增不仅局限于有创活检样本,而且也是低细菌生物量呼吸(黏膜)样本中的一个问题,特别是当细菌生物量低于 0.3pg/μL 时,扩展了之前的发现。我们表明,通过使用基于凝胶的文库纯化方法,可以部分减轻非靶向扩增。重要的是,我们报告了在使用 MiSeq 试剂试剂盒 v3 时,与 v2 相比,非靶向扩增子的检测率更高(分别为平均 13.3%和 0.1%的非靶向读取/样本),这可能是由于试剂或测序方案的差异所致。然而,由于在生物信息学去除非靶向读取后,MiSeq 试剂试剂盒 v3 与 v2 相比仍然产生两倍多的读取数,因此仍然优先选择 v3 而不是 v2。总之,这些结果增加了关于非靶向扩增和检测的知识基础,使研究人员能够在涉及低生物量样本的基于 16S-rRNA 的微生物组研究中预测到这个问题。